This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A look at the Safety and Efficacy of BLU-5937 in the Treatment of Refractory Chronic Cough
Ticker(s): BLUWho's the expert?
Institution: Kings College Hospital
- Pulmonologist, Consultant Respiratory Physician and Professor of Respiratory Medicine at King’s College Hospital, head of specialist cough clinic at Kings in London
- Set up a specialist cough clinic and research team, serving Southern England.
- Leading research into the mechanisms, monitoring and treatment of cough; has led the development of a number of widely used patient reported outcome measures for Interstitial Lung Disease, Sarcoidosis, Bronchiectasis and Cough and has also led a number of clinical trials of antitussive therapies that include Cromolyn (PA101), Diphenhydramine, Physiotherapy/Speech Therapy, and as co-investigator for Gabapentin, Pregabalin and P2X3 inhibitor MK7264.
Interview GoalA look at the Safety and Efficacy of BLU-5937 in the Treatment of Refractory Chronic Cough
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
